Ho S - Search Results

1

Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report.

Lee K, Chan K, Leung WT, Leung NW, Ho S, Chan M, Lau CC, Tao M, Lau WY, Shiu W. Lee K, et al. Among authors: ho s. Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):221-6. doi: 10.1007/BF03190149. Eur J Drug Metab Pharmacokinet. 1992. PMID: 1337040

2

Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma.

Leung WT, Lau WY, Ho S, Chan M, Leung N, Lin J, Ho KC, Metreweli C, Johnson PJ, Li AK. Leung WT, et al. Among authors: ho s, ho kc. J Nucl Med. 1994 Aug;35(8):1313-8. J Nucl Med. 1994. PMID: 7519259 Free article. Clinical Trial.

3

Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study.

Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, Metreweli C, Johnson P, Li AK. Lau WY, et al. Among authors: ho s. Br J Cancer. 1994 Nov;70(5):994-9. doi: 10.1038/bjc.1994.436. Br J Cancer. 1994. PMID: 7947110 Free PMC article. Clinical Trial.

4

Expression of beta-2-microglobulin by nasopharyngeal carcinoma.

Shiu W, Leung SF, Leung WT, Ho S, Tao M. Shiu W, et al. Among authors: ho s. Br J Cancer. 1992 Sep;66(3):555-7. doi: 10.1038/bjc.1992.313. Br J Cancer. 1992. PMID: 1520593 Free PMC article.

5

'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.

Johnson PJ, Leung N, Cheng P, Welby C, Leung WT, Lau WY, Yu S, Ho S. Johnson PJ, et al. Among authors: ho s. Br J Cancer. 1997;75(2):236-40. doi: 10.1038/bjc.1997.39. Br J Cancer. 1997. PMID: 9010032 Free PMC article.

6

Arteriovenous shunts in patients with hepatic tumors.

Ho S, Lau WY, Leung WT, Chan M, Chan KW, Johnson PJ, Li AK. Ho S, et al. J Nucl Med. 1997 Aug;38(8):1201-5. J Nucl Med. 1997. PMID: 9255149 Free article.

7

Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.

Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK. Lau WY, et al. Among authors: ho r, ho s. Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):583-92. doi: 10.1016/s0360-3016(97)00818-3. Int J Radiat Oncol Biol Phys. 1998. PMID: 9486608

8

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.

Yeo W, Chan KK, Mukwaya G, Ross M, Leung WT, Ho S, Chan AT, Johnson PJ. Yeo W, et al. Among authors: ho s. Cancer Chemother Pharmacol. 1999;44(2):124-30. doi: 10.1007/s002800050956. Cancer Chemother Pharmacol. 1999. PMID: 10412946 Clinical Trial.

9

What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres?

Lau WY, Ho S, Leung WT, Chan M, Lee WY, Johnson PJ. Lau WY, et al. Among authors: ho s. Hepatogastroenterology. 2001 Mar-Apr;48(38):338-40. Hepatogastroenterology. 2001. PMID: 11379304

10

Combating hepatocellular carcinoma with an integrated approach.

Ho S, Johnson PJ, Leung WT, Lau WY. Ho S, et al. Chin Med J (Engl). 1999 Jan;112(1):80-3. Chin Med J (Engl). 1999. PMID: 11593648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,146 results

Search Page

Filters